SAN CARLOS, Calif. and HOPKINTON, Mass., Jan. 15, 2019 /PRNewswire/ -- LakePharma, Inc., the leading US-based biologics contract research, development, and manufacturing organization (CRDMO), announced today that their GMP biorepository facility is now commercially operational at their Hopkinton, MA location, which is in close proximity to the Cambridge and Boston areas.
The GMP biorepository facility is a part of LakePharma's GMP microBiomanufacturing™ Center, which began operations last month and is currently producing GMP-grade plasmid DNA. The GMP biorepository facility is dedicated to storing drug developers' materials in various temperature conditions ranging from -135°C to 8°C, with state-of-the-art temperature alarm monitoring, secured keycard access, and comprehensive emergency recovery procedures.
"The introduction of our GMP biorepository complements our GMP manufacturing services and furthers our ability to offer an end-to-end client solution. The market demand for cGMP services continues to expand, and LakePharma expects to participate in that growth. We will scale our manufacturing capabilities and plan on hiring an additional 50 staff this year," said Hua Tu, CEO of LakePharma.
For more information, please visit www.lakepharma.com/biorepository
LakePharma is the leading US-based biologics contract research, development, and manufacturing organization (CRDMO). The company has developed a range of technologies and capabilities in antibody discovery, protein engineering, cell line development, process optimization, and GMP manufacturing. With comprehensive technologies, integrated platforms, and five facilities located in key biopharma hubs on both the East and West Coast, LakePharma enables and supports the discovery and development of the biologics of tomorrow.
Senior Manager, Marketing & Communications
SOURCE LakePharma, Inc.